Yasuhiko Nakamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yasuhiko Nakamura has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Ichiro Miwa
Department of Obstetrics and Gynecology, Yamaguchi Grand Medical Center, Hofu, Japan
2 shared publicationsHiromi Sanai
Department of Obstetrics and Gynecology, Yamaguchi Grand Medical Center, Hofu, Japan
1 shared publication- Hiromi Sanai
Department of Obstetrics and Gynecology Yamaguchi Prefectural Grand Medical Center Hofu Yamaguchi Japan
1 shared publication - Ichiro Miwa
Department of Obstetrics and Gynecology, Yamaguchi Grand Medical Center, 77 Oosaki, Houhu, 747-8511 Japan
1 shared publication Isao Tamura
Department of Obstetrics and Gynecology, Yamaguchi Grand Medical Center, Yamaguchi, Japan
1 shared publication- Kazuyuki Ueda
Department of Obstetrics and Gynecology, Yamaguchi Grand Medical Center, 77 Oosaki, Houhu, 747-8511 Japan
1 shared publication
Latest Publications
- Open Access
- 1 January 2018
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 6
Remarkable response of recurrent endometrial adenocarcinoma to daily oral administration of half-dose etoposide
A 71-year-old woman with right chest and left lumbar pain was referred to our hospital. Computed tomography showed multiple recurrent tumors in the abdominal cavity and bilateral lungs. She had already received several chemotherapies for the recurrent tumor, and palliative care would be appropriate. However, she was seeking another anti-cancer therapy. Therefore, she was told about low-dose etoposide therapy and consented to its administration. Treatment was very effective; serum tumor marker levels decreased dramatically, the pain was controlled, and the recurrent masses were shrinking. However, her recurrent tumor had become refractory again in the 22nd month of treatment.
- 1 January 2018
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 6
Open AccessRemarkable response of recurrent endometrial adenocarcinoma to daily oral administration of half-dose etoposide
A 71-year-old woman with right chest and left lumbar pain was referred to our hospital. Computed tomography showed multiple recurrent tumors in the abdominal cavity and bilateral lungs. She had already received several chemotherapies for the recurrent tumor, and palliative care would be appropriate. However, she was seeking another anti-cancer therapy. Therefore, she was told about low-dose etoposide therapy and consented to its administration. Treatment was very effective; serum tumor marker levels decreased dramatically, the pain was controlled, and the recurrent masses were shrinking. However, her recurrent tumor had become refractory again in the 22nd month of treatment.
- 16 December 2014
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 41 (5) , 809-812
Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan
Primary ovarian squamous cell carcinoma is uncommon, and the optimal treatment strategy for this disease has not yet been established. A 71‐year‐old woman diagnosed with FIGO stage IIb pure ovarian squamous cell carcinoma underwent cytoreductive surgery followed by combination chemotherapy with paclitaxel and carboplatin. After the second treatment course, a recurrent mass grew rapidly, and serum tumor maker levels increased. Monotherapy with weekly irinotecan was then instituted. This second‐line chemotherapy was remarkably effective, and the patient subsequently underwent complete interval debulking surgery with a pathological complete response after the third treatment course. Weekly irinotecan is an effective choice for primary ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin.
- 16 December 2014
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 41 (5) , 809-812
Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan
Primary ovarian squamous cell carcinoma is uncommon, and the optimal treatment strategy for this disease has not yet been established. A 71‐year‐old woman diagnosed with FIGO stage IIb pure ovarian squamous cell carcinoma underwent cytoreductive surgery followed by combination chemotherapy with paclitaxel and carboplatin. After the second treatment course, a recurrent mass grew rapidly, and serum tumor maker levels increased. Monotherapy with weekly irinotecan was then instituted. This second‐line chemotherapy was remarkably effective, and the patient subsequently underwent complete interval debulking surgery with a pathological complete response after the third treatment course. Weekly irinotecan is an effective choice for primary ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin.
- Open Access
- 11 July 2014
- Published by Springer Nature in SpringerPlus
- Vol. 3 (1) , 1-4
A thick placenta: a predictor of adverse pregnancy outcomes
The aim of this study is to evaluate the efficacy of an ultrasonographic measurement of placental thickness and the correlation of a thick placenta with adverse perinatal outcome. Placental thickness was measured in single gravidas, 16 to 40 weeks of gestation, between 2005 and 2009. Placentas were considered to be thick if their measured thickness were above the 95th percentile for gestational age. The incidence of thick placentas was 4.3% (138/3,183). Perinatal morbidity and neonatal conditions were worse in cases with thick placenta rather than without thick placenta. Ultrasonographic measurement of placental thickness is a simple method to estimate placental size. Thick placenta may be a useful predictor of adverse pregnancy outcomes.
- 11 July 2014
- Published by Springer Nature in SpringerPlus
- Vol. 3 (1) , 1-4
Open AccessA thick placenta: a predictor of adverse pregnancy outcomes
The aim of this study is to evaluate the efficacy of an ultrasonographic measurement of placental thickness and the correlation of a thick placenta with adverse perinatal outcome. Placental thickness was measured in single gravidas, 16 to 40 weeks of gestation, between 2005 and 2009. Placentas were considered to be thick if their measured thickness were above the 95th percentile for gestational age. The incidence of thick placentas was 4.3% (138/3,183). Perinatal morbidity and neonatal conditions were worse in cases with thick placenta rather than without thick placenta. Ultrasonographic measurement of placental thickness is a simple method to estimate placental size. Thick placenta may be a useful predictor of adverse pregnancy outcomes.
- 1 January 2008
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 24 (12) , 708-712
A novel mutation in exon8 of the follicle-stimulating hormone receptor in a woman with primary amenorrhea
The FSH receptor (FSHR) gene mutation are rare, but recently have been detected in several cases with primary amenorrhea. We report a 25-year-old female who had primary amenorrhea, moderately developed secondary sex characteristics and normal sized ovaries with small antral follicles. Her ovaries reacted slightly to clomiphene citrate therapy; they did not react to the ordinary dose of human menopausal gonadotropin (hMG) (150 IU/day × 9 days), but did react to high-dose hMG (300 IU/day × 6 days) treatment. These ovarian responses to hMG stimulation suggested an FSHR dysfunction of her ovaries. We extracted genomic DNA and analysed FSHR gene sequence after we obtained the written informed consent from the patient under the approval by the Ethics Committee of Yamaguchi Grand Medical Centre and the Yamaguchi University School of Medicine. Direct sequencing revealed a heterozygous mutation 662T−>G resulting in the substitution of valine for glycine at position 221 in exon8 of the FSHR extracellular domain, which was also confirmed by the PCR-RFLP method. The sequencing results also showed two SNPs, 919G−>A (Ala307Thr) and 2039G−>A (Ser680Asn), in exon10. A novel mutation in exon8 of FSHR was identified in a woman with primary amenorrhea whose ovaries reacted to high-dose hMG treatment.
- 1 January 2008
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 24 (12) , 708-712
A novel mutation in exon8 of the follicle-stimulating hormone receptor in a woman with primary amenorrhea
The FSH receptor (FSHR) gene mutation are rare, but recently have been detected in several cases with primary amenorrhea. We report a 25-year-old female who had primary amenorrhea, moderately developed secondary sex characteristics and normal sized ovaries with small antral follicles. Her ovaries reacted slightly to clomiphene citrate therapy; they did not react to the ordinary dose of human menopausal gonadotropin (hMG) (150 IU/day × 9 days), but did react to high-dose hMG (300 IU/day × 6 days) treatment. These ovarian responses to hMG stimulation suggested an FSHR dysfunction of her ovaries. We extracted genomic DNA and analysed FSHR gene sequence after we obtained the written informed consent from the patient under the approval by the Ethics Committee of Yamaguchi Grand Medical Centre and the Yamaguchi University School of Medicine. Direct sequencing revealed a heterozygous mutation 662T−>G resulting in the substitution of valine for glycine at position 221 in exon8 of the FSHR extracellular domain, which was also confirmed by the PCR-RFLP method. The sequencing results also showed two SNPs, 919G−>A (Ala307Thr) and 2039G−>A (Ser680Asn), in exon10. A novel mutation in exon8 of FSHR was identified in a woman with primary amenorrhea whose ovaries reacted to high-dose hMG treatment.